335 clinical trials
grid
list
download
| Body (indexed field) | Identifiant (ID) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 22618 | metastatic, RECIST 1.1 | Yassine Lalami | Oral cavity and lips | EORTC | 1206 - HNCG | Trial closed for recruitment | A randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic, androgen receptor (AR) expressing, salivary gland cancer (SGCs) | yassine.lalami@hubruxelles.be | 2 | 2 | |
| 22757 | 1st line / >= 60 years old / Eligible for standard intensive chemotherapy/ De novo or secondary AML is allowed | Dominique Bron | Acute leukemia | EORTC | 1301-LG | Trial closed for recruitment | 10-day decitabine versus conventional chemotherapy (?3+7?) followed by allografting in AML patients >= 60 years: a randomized phase III study of the EORTC Leukemia Group, CELG, GIMEMA and German MDS Study Group | dominique.bron@hubruxelles.be | 3 | 3 | |
| 22620 | any line, RECIST 1.1 | Ahmad Hussein Awada | Multiple | Boehringer Ingelheim | 1367.1 | Trial closed | An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit | ahmad.awada@hubruxelles.be | 1 | 1 | |
| 22626 | Germ cell tumor | Thierry Gil | Testicles | EORTC | 1407 GUCC TIGER | Trial closed for recruitment | A Randomized phase III trial comparing conventional-dose chemotherapy using paclitaxel, ifosfamide, and cisplatin (TIP) with high dose chemotherapy using mobilizing paclitaxel plus ifosfamide followed by high-dose carboplatin and etoposide (TI-CE) as first salvage treatment in relapsed or refractory germ cell tumors | thierry.gil@hubruxelles.be | 3 | 3 | |
| 29695 | Mariana Brandao | Lung | Boehringer Ingelheim | 1479-0001 | Trial open for recruitment | An open label, Phase I dose escalation trial, with dose confirmation and expansion, of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations. | mariana.brandao@hubruxelles.be | 1 | 1 | ||
| 29750 | Michail Ignatiadis | Breast | EORTC | 2129 - TREAT ctDNA | Trial open for recruitment | Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA) | michail.ignatiadis@hubruxelles.be | 3 | 3 | ||
| 22697 | Treatment by Immunotherapy <6months Admission in intensive care |
Anne-Pascale Meert | Solid tumors | CHU de Grenoble | 38RC17.290 | Trial closed for recruitment | Characteristics and Care of Solid Tumor Patients Treated With Immunotherapy Admitted in Intensive Care Unit. | ap.meert@hubruxelles.be | |||
| 29694 | Francesco Sclafani | Multiple | Janssen | 61186372GIC2002 ORIGAMI-1 | Trial open for recruitment | A Phase 1b/2, Open-Label Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants with Advanced or Metastatic Colorectal Cancer | francesco.sclafani@hubruxelles.be | 1/2 | 1 | ||
| 22685 | Unresecable or metastatic | Amelie Deleporte | Stomach - Duodenum-esogastric junction | Astellas | 8951-CL-0301 | Trial closed for recruitment | A Phase 3, Global, Multi-Center, Double-Blind, Randomized, Efficacy Study of IMAB362 Plus mFOLFOX6 Compared with Placebo Plus mFOLFOX6 as First-line Treatment of Subjects with Claudin (CLDN)18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | amelie.deleporte@hubruxelles.be | 3 | 3 | |
| 22817 | c-Kit positive. Progression under imatinib | Thierry Gil | Stomach - Duodenum-esogastric junction | AB Science | AB11002 | Trial closed | AB11002 A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib to sunitinib in patients with gastrointestinla stromal tumor after progression with imatinib. | thierry.gil@hubruxelles.be | 3 | 3 | |
| 22709 | 4 lines chemotherapy and radiation | Bogdan Grigoriu | Lung | AstraZeneca | ADRIATIC | Trial closed for recruitment | A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with Stage I-III Limited Disease Small-Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (D933QC00001 - ADRIATIC) | Bogdan.Grigoriu@hubruxelles.be | 3 | 3 | |
| 22684 | No prior gene therapy | Dirk Van Gestel | Head and Neck | Oragenics | AG013-ODOM-201 | Trial closed | A Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of topically-applied AG013 for the attenuation of oral mucositis in subjects with cancers of the head and neck receiving concomitant chemoradiation therapy | accueil.cons.radiotherapie@hubruxelles.be | 2 | 2 | |
| 28802 | Philippe Aftimos | Breast | Ayala Pharmaceuticals, Inc. | AL-TNBC-01 - TENACITY | Trial closed | A Phase 2, Multicenter, Open-label, Single arm Study of AL101 Monotherapy in Patients with Notch Activated Triple Negative Breast Cancer | philippe.aftimos@hubruxelles.be | 2 | 2 | ||
| 22698 | Unresacable metastasis. RECIST v1.1. Can receive FOLFOX | Alain Hendlisz | Colon | Celyad | Allo-Shrink | Trial closed | An open-label, Phase I study to assess the safety of multiple doses of CYAD-101, administered after standard FOLFOX chemotherapy in patients with unresectable metastatic colorectal cancer | alain.hendlisz@hubruxelles.be | 1 | 1 |